Industries > Pharma > Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030

Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

PUBLISHED: 17 February 2020
PAGES: 177
PRODUCT CODE: PHA0713

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

covid-19

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 177-page report you will receive 100 charts– all unavailable elsewhere.

The 177-page report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2020-2030

• Profiles of the leading 26 asthma & COPD companies:
• Adamis Pharmaceuticals Corporation
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Dimerix
• GlaxoSmithKline
• Innoviva
• Lallemand Pharma International
• Merck
• Mereo BioPharma Group plc
• MundiPharma
• Novartis
• Pulmatrix
• Respiratorius AB
• Roche
• Other companies

Top 26 Asthma & COPD Companies 2020-2030

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2020-2030
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

• Key questions answered by this report:
• How is the Asthma & COPD Companies market evolving?
• What is driving and restraining the Asthma & COPD Companies market?
• What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
• What will be the main driver for the overall market from 2019 to 2030?
• Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry evolve during the period between 2019 and 2030?

Visiongain’s study is intended for anyone requiring commercial analyses for the top 26 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 26 Asthma & COPD Companies: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ